BCR-ABL–induced adhesion defects are tyrosine kinase–independent
- 1 June 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 99 (11) , 4122-4130
Abstract
The t(9;22) chromosomal translocation results in expression of P210BCR-ABL, a fusion protein necessary for the development of chronic myelogenous leukemia (CML). The constitutive activation of the P210BCR-ABL tyrosine kinase results in phosphorylation of multiple signaling pathways leading to the transformed phenotype. Additionally, extracellular interactions between P210BCR-ABL–expressing progenitor cells and bone marrow stroma may provide external signals that facilitate CML development. In contrast to the intracellular signaling pathways involved in CML, little is known about how P210BCR-ABLexpression modifies cell-cell and cell-substratum interactions. To investigate the role of P210BCR-ABL in modulating cellular adhesion, we used a highly sensitive and quantitative cell detachment apparatus that measures the strength of association between a population of cells and an adhesive matrix. Our findings show that P210BCR-ABL expression increased adhesion nearly 2-fold between the myeloblastic cell line, 32D, and fibronectin compared to a control vector. We then investigated whether abnormal adhesion due to P210BCR-ABL expression was caused by its tyrosine kinase activity. A quantitative analysis of cell-fibronectin adhesion found that neither expression of a kinase-inactive P210BCR-ABL mutant in 32D cells or attenuation of kinase activity by STI571 (imatinib mesylate) in 32D cells transduced with wild-type P210BCR-ABL could correct the nearly 2-fold increase in cell-fibronectin adhesion. Similarly, STI571 treatment of Meg-01 cells, a P210BCR-ABL–expressing cell line derived from a patient in blast crisis, failed to inhibit adhesion to fibronectin. Together, our results indicate that changes in adhesion induced by P210BCR-ABL are independent of its tyrosine kinase activity.Keywords
This publication has 43 references indexed in Scilit:
- Distinct Ligand-binding Modes for Integrin αvβ3-Mediated Adhesion to Fibronectinversus VitronectinJournal of Biological Chemistry, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Two-stage Activation for α5β1Integrin Binding to Surface-adsorbed FibronectinJournal of Biological Chemistry, 1998
- Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores β1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitorsLeukemia, 1998
- BCR/ABL induces multiple abnormalities of cytoskeletal function.Journal of Clinical Investigation, 1997
- Bcr/Abl expression stimulates integrin function in hematopoietic cell lines.Journal of Clinical Investigation, 1996
- c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism.Genes & Development, 1995
- The hematopoietic microenvironmentCritical Reviews in Oncology/Hematology, 1991
- A novel tyrosine kinase-independent function of Drosophila abl correlates with proper subcellular localizationCell, 1990